Applied Therapeutics Inc (NASDAQ:APLT)’s traded shares stood at 3.98 million during the last session, with the company’s beta value hitting 1.94. At the close of trading, the stock’s price was $0.38, to imply a decrease of -13.23% or -$0.06 in intraday trading. The APLT share’s 52-week high remains $10.62, putting it -2694.74% down since that peak but still an impressive 23.68% since price per share fell to its 52-week low of $0.29. The company has a valuation of $53.50M, with an average of 3.83 million shares in intraday trading volume over the past 10 days and average of 2.34 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Applied Therapeutics Inc (APLT), translating to a mean rating of 2.25. Of 3 analyst(s) looking at the stock, 0 analyst(s) give APLT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.17.
Applied Therapeutics Inc (NASDAQ:APLT) trade information
After registering a -13.23% downside in the last session, Applied Therapeutics Inc (APLT) has traded red over the past five days. The 5-day price performance for the stock is -22.11%, and 9.85% over 30 days. With these gigs, the year-to-date price performance is -55.86%. Short interest in Applied Therapeutics Inc (NASDAQ:APLT) saw shorts transact 15.83 million shares and set a 6.77 days time to cover.
The extremes give us $4 and $5 for target low and target high price respectively. As such, APLT has been trading -1215.79% off suggested target high and -952.63% from its likely low.
Applied Therapeutics Inc (APLT) estimates and forecasts
The rating firms project that company’s revenue will grow 174.73% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 416.67k. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 416.67k.Earnings reports from the last fiscal year show that sales brought in 144k and 122k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 189.35% before jumping 241.53% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 26.57% for the past 5-year period. While 2025 is set for a 23.30% return in earnings, projections for the next 5 years are at 24.56% annually.
APLT Dividends
Applied Therapeutics Inc has its next earnings report out on 2025-May-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Applied Therapeutics Inc (NASDAQ:APLT)’s Major holders
Applied Therapeutics Inc insiders hold 4.90% of total outstanding shares, with institutional holders owning 83.01% of the shares at 87.29% float percentage. In total, 83.01% institutions holds shares in the company, led by FRANKLIN RESOURCES INC. As of 2024-06-30, the company held over 10.21 million shares (or 70.7533% of shares), all amounting to roughly $47.69 million.
The next major institution holding the largest number of shares is VR ADVISER, LLC with 9.54 million shares, or about 66.1112% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $44.57 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Small-Cap Value Fund, Inc. as the top two Mutual Funds with the largest holdings of the Applied Therapeutics Inc (APLT) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 3.1 shares. This is just over 2.19% of the total shares, with a market valuation of $1.17 million. Data from the same date shows that the other fund manager holds a little less at 3.04, or 2.15% of the shares, all valued at about 1.15 million.
